RJA
PRTK

Raymond James & Associates’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Raymond James & Associates’s Portfolio PRTK Stock Details PRTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-29,198
Closed -$199K – 4298
2021
Q2 		$199K Buy
29,198
+4,738
+19% +$38.3K ﹤0.01% 3689
2021
Q1 		$173K Sell
24,460
-101,748
-81% -$733K ﹤0.01% 3652
2020
Q4 		$790K Sell
126,208
-11,554
-8% -$68K ﹤0.01% 2494
2020
Q3 		$745K Buy
137,762
+101,864
+284% +$504K ﹤0.01% 2362
2020
Q2 		$187K Sell
35,898
-1,050
-3% -$4.66K ﹤0.01% 3153
2020
Q1 		$116K Sell
36,948
-9,400
-20% -$34.7K ﹤0.01% 3186
2019
Q4 		$187K Sell
46,348
-11,975
-21% -$41.5K ﹤0.01% 3368
2019
Q3 		$252K Sell
58,323
-25,800
-31% -$103K ﹤0.01% 3113
2019
Q2 		$336K Sell
84,123
-5,742
-6% -$27.3K ﹤0.01% 2936
2019
Q1 		$482K Sell
89,865
-8,663
-9% -$55.9K ﹤0.01% 2670
2018
Q4 		$505K Sell
98,528
-147
-0.1% -$1.12K ﹤0.01% 2550
2018
Q3 		$957K Buy
98,675
+10,102
+11% +$102K ﹤0.01% 2285
2018
Q2 		$903K Buy
88,573
+79
+0.1% +$894 ﹤0.01% 2285
2018
Q1 		$1.15M Buy
88,494
+64,337
+266% +$958K ﹤0.01% 2032
2017
Q4 		$432K Buy
24,157
+12,632
+110% +$264K ﹤0.01% 2623
2017
Q3 		$289K Buy
+11,525
New +$268K ﹤0.01% 2822

Other funds holding PRTK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
BC
Bruce & Co Chicago, Illinois $350M AUM 33.5% 1-Year Est. Return
GAI
General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Raymond James & Associates's PRTK Position: Q3 2021 in Review

Raymond James & Associates sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q3 2021, closing a stake of 29,198 shares — an estimated $199K sold.

Raymond James & Associates first reported a position in PRTK in Q3 2017 and held it in 16 quarters. The position peaked at $1.15M in Q1 2018. 105 funds tracked by Wall St. Rank hold PRTK as of Q3 2021.

  • Raymond James & Associates reported no remaining Paratek Pharmaceuticals, Inc. position as of Q3 2021 after selling out during the quarter.
  • Raymond James & Associates sold 29,198 Paratek Pharmaceuticals, Inc. shares in Q3 2021, an estimated $199K.
  • Raymond James & Associates first reported a position in Paratek Pharmaceuticals, Inc. in Q3 2017 and held it in 16 quarters.
  • Raymond James & Associates's Paratek Pharmaceuticals, Inc. position peaked at $1.15M in Q1 2018.
  • 105 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q3 2021.

Based on Raymond James & Associates's 13F filing for Q3 2021, filed 2 Nov 2021.